Polyrizon Ltd. Ordinary Shares PLRZ 深 沪
等待开盘 12-20 09:30:00 美东时间
9.1845
-0.925
-9.15%
华盛通- 最 高18.20
- 今 开10.09
- 成交量 10.41万股
- 最 低 0.48
- 昨 收 10.11
- 总市值 0
- 52周最高 18.20
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 0.0032
- 委 比 -81.82%
- 总股本 --
- 历史最高 18.20
- 量 比 0.66
- 振 幅 175.27%
- 历史最低 0.0032
- 每 手 1
- 风险率 2.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What Sparked Polyrizon's (PLRZ) 140% After-Hours Stock Surge?
Polyrizon surged in nearly 140% after-hours trading following preclinical data showing its naloxone hydrogel outperforms a marketed spray and a key manufacturing milestone.
12-04 10:52
Gold Down Over 1%; Signet Shares Fall After Q3 Results
U.S. stocks traded higher midway through trading, with the Dow Jones gaining ar...
12-03 01:29
Nasdaq Surges 200 Points; United Natural Foods Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining aroun...
12-02 22:50
Polyrizon Completes Manufacturing Upscaling Milestone For Its Proprietary Nasal-Spray Product Platform
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced the successful
12-02 20:57
Polyrizon Announces Positive In-Vitro Results For Its PL-16 Viral Blocker Candidate Against H1N1 Influenza
Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company developing intranasal products based on its proprietary Capture & Contain (C&C) platform, today announced positive in-vitro
11-06 21:58
Polyrizon Announces Receipt of Nasdaq Delisting Notice
Polyrizon Ltd. received a delisting notification from Nasdaq due to shareholder dilution concerns from its securities issuance. The company plans to request a hearing to appeal the decision, which will suspend any delisting actions pending the outcome.
05-23 20:15
Polyrizon Reports Initiation Of Preclinical Studies For Intranasal Naloxone For Opioid Overdose Treatment
The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and
03-10 19:50
